PMID: 8611475Apr 1, 1996Paper

Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns

British Journal of Haematology
R E GaleD C Linch

Abstract

Autologous bone marrow or peripheral blood stem cell transplantation may carry an increased risk of secondary myelodysplasia (MDS) and acute myeloid leukaemia (AML), which are already recognized as complications of conventional treatment for lymphoid malignancies. In order to ascertain whether it is possible to detect the evolution of such a clone at an early stage in its development we have studied X-chromosome inactivation patterns (XCIPs) in three informative females who developed abnormal myelopoiesis after high-dose chemotherapy and ABMT. In one patient transplanted for relapsed Hodgkin's disease a leukaemic clone comprising approximately 50% of the patient's myeloid cells was detectable by comparison of peripheral blood granulocyte and T-cell XCIPs when the full blood count and morphology were normal. She presented with AML 7 months later. In two patients transplanted for AML, XCIP analysis was complicated by constitutively skewed Lyonization patterns, nevertheless a progressive alteration could be demonstrated by serial analyses. In one patient a difference was detectable 28 months before presentation with MDS. In the other patient, despite evident mild pancytopenia and alterations in her XCIPs over the past 4 years, she...Continue Reading

Citations

Mar 10, 1999·Leukemia Research·G Lambertenghi DeliliersL Romitti
Mar 10, 1999·Leukemia Research·H D Preisler
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·Martin BorgAnthony C Thomas
Sep 1, 1993·British Journal of Haematology·R E Gale, J S Wainscoat
Aug 1, 1994·British Journal of Haematology·R E Gale, D C Linch
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·J L AbkowitzJ V Kiklevich
Sep 12, 1998·British Journal of Haematology·L TononM Cazzola
Mar 8, 2000·Leukemia & Lymphoma·H D PreislerA Raza
Apr 28, 2000·Leukemia & Lymphoma·B LiH D Preisler
Feb 24, 2011·Blood·Sandra N CatlinJanis L Abkowitz
Jan 1, 1998·Hematology·D J Culligan
Nov 26, 2002·Hematology·John R WingardH Joachim Deeg
May 24, 2003·Bulletin of Entomological Research·V JarosíkJ Havelka
Feb 22, 2021·Blood Cells, Molecules & Diseases·Maria Carolina Costa Melo SvidnickiSara Teresinha Olalla Saad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.